← Product Code [GEX](/productcode/GEX) · K221623 # FlexSys, FlexSys UVB EPL 308 nm, FlexSys UVB EPL lite 308 nm, FlexSys IR 1550 nm (K221623) _Gme German Medical Engineering GmbH · GEX · Mar 10, 2023 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K221623 ## Device Facts - **Applicant:** Gme German Medical Engineering GmbH - **Product Code:** [GEX](/productcode/GEX.md) - **Decision Date:** Mar 10, 2023 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4810 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Indications for Use The device FlexSys is a multi-modality skin surface treatment system. Depending on the chosen modules the intended use and the mode of operation varies. Modules UVB EPL 308 and UVB EPL 308 lite: The GME FlexSys System with module UVB EPL 308 or UVB EPL 308 lite is intended to be used for the treatment of psoriasis and vitiligo. It is to be used on intact skin only. Module Infrared 1550: The GME FlexSys System with Infrared 1550 module is indicated for use in dermatological procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures. It is also indicated for treatment of dyschromia and cutaneous lesions, such as, but not limited to lentigos (age spots), solar lentigos (sun spots), actinic keratosis, and melasma, and for treatment of periorbital wrinkles, acne scars and surgical scars. ## Device Story Multi-modality skin surface treatment system; base unit with touch-screen control; connects to interchangeable laser modules (UVB EPL 308, UVB EPL 308 lite, Infrared 1550) via electrical cables and optical fibers. Handpieces/scanners direct laser light onto skin via mirrors and lenses; spot size varies with distance. UVB modules modulate immune system/stimulate melanocytes; Infrared 1550 module heats water in skin to denature tissue and stimulate healing. Operated by clinicians in dermatological settings. Output affects tissue via coagulation or phototherapy; benefits include lesion removal, skin resurfacing, and treatment of dermatological conditions. ## Clinical Evidence Bench testing only. No clinical data presented. Performance verified through adherence to international safety standards for laser products (IEC 60825-1) and medical electrical equipment (IEC 60601-1, IEC 60601-2-22, IEC 60601-1-2). ## Technological Characteristics Multi-modality laser system; base unit with touch-screen interface; interchangeable handpieces/scanners; optical fiber delivery; 308nm UVB and 1550nm infrared wavelengths. Complies with IEC 60825-1 (laser safety), IEC 60601-2-22 (laser equipment safety), IEC 60601-1 (general safety), and IEC 60601-1-2 (EMC). ## Regulatory Identification (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon. ## Predicate Devices - Solta Medical Inc., Fraxel DUAL 1550/1927 Laser System ([K130193](/device/K130193.md)) - GME ExSys 308 ([K150752](/device/K150752.md)) - Clarteis Exciplex308nm ([K171702](/device/K171702.md), [K191086](/device/K191086.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG ADMINISTRATION' in blue text. March 10, 2023 GME German Medical Engineering GmbH Dietmar Fischer Technical Director Dreikoenigstr. 6-8 Erlangen, Bavaria 91054 Germany Re: K221623 Trade/Device Name: FlexSys, FlexSys UVB EPL 308 nm, FlexSys UVB EPL lite 308 nm, FlexSys IR 1550 nm Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX, FTC Dated: December 6, 2022 Received: December 12, 2022 Dear Dietmar Fischer: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. # Jianting Wang -S Jianting Wang Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K221623 Device Name FlexSys #### Indications for Use (Describe) The device FlexSys is a multi-modality skin surface treatment system. Depending on the chosen modules the intended use and the mode of operation varies. #### Modules UVB EPL 308 and UVB EPL 308 lite: The GME FlexSys System with module UVB EPL 308 or UVB EPL 308 lite is intended to be used for the treatment of psoriasis and vitiligo. It is to be used on intact skin only. #### Module Infrared 1550: The GME FlexSys System with Infrared 1550 module is indicated for use in dermatological procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures. It is also indicated for treatment of dyschromia and cutaneous lesions, such as, but not limited to lentigos (age spots), solar lentigos (sun spots), actinic keratosis, and melasma, and for treatment of periorbital wrinkles, acne scars and surgical scars. | Type of Use (Select one or both, as applicable) | |-------------------------------------------------| |-------------------------------------------------| X Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ # 510(k) Summary K221623 This 510(k) Summary is submitted in accordance with the requirements of 21 CFR 807.92. Summary preparation date 2023-03-08 [21 CFR 807.92(a)(1)]. #### A. Applicant Name and Address [21 CFR 807.92(a)(1)] GME German Medical Engineering GmbH. Dreikoenigstrasse 6-8 91054 Erlangen Bavaria, Germany Tel: +49 9131 934159 10 Fax: +49 9131 934159 99 #### B. Contact Information GME German Medical Engineering GmbH. Dreikoenigstrasse 6-8 91054 Erlangen Bavaria, Germany Contact person: Dr. Dietmar Fischer Dietmar.fischer@gmeonline.de #### C. Device Trade Name, Common Name, Classification [21 CFR 807.92(a)(2)] Trade Name: FlexSys Device Common Name: Laser Instrument for Dermatology Classification Name: Laser Instrument, Surgical Powered 21 CFR 878.4810 Product Code: GEX, FTC Device Classification: Class II #### D. Predicate Devices [21 CFR 807.92(a)(3)] The FleySys uses similar technology and physical output characteristics as the following predicate devices: K130193 Solta Medical Inc., Fraxel DUAL 1550/1927 Laser System K150752 GME ExSys 308 K171702, K191086 Clarteis Exciplex308nm #### E. Device Description [21 CFR 807.92(a)(4)] The device FlexSys consists of a base unit with up to two installed internal laser modules, handpieces and/or scanners for these modules and attachable applicators. All applicators, handpieces, and scanners are connected by an electrical cable. The base unit contains most of the controls, such as the touch-screen, the on / off switch or the emergency stop button. In addition, the power cord, foot switch, and the door plug are connected there. The touch-screen serves as the main control panel. {4}------------------------------------------------ The applicators, handpieces, and scanners direct the light onto the skin. Some applicators contain a hand switch on the front of the handle by which light emission can be triggered. The scanners and handpieces of the internal modules are connected to the base unit by an electric signal cable and by an optical fiber which guides the aiming beam and working beam laser light to the handpiece/scanner in its core. The light is then guided onto the skin via several mirrors and lenses. Due to the round shape of the fiber core the resulting laser spot on the skin is circular. The size of the working beam spot corresponds to the nominal value when the distance tip touches the skin. For larger distances the spot size will increase, i.e. the laser beam is divergent. During development and manufacturing applicable directives, legal requirements and standards for medical devices were considered. Our product complies to them. # F. Indications for Use [21 CFR 807.92(a)(5)] The device FlexSys is a multi-modality skin surface treatment system. Depending on the chosen modules the intended use and the mode of operation varies. #### Modules EPL 308 and EPL 308 lite: The GME Flex.Sys System with module EPL 308 lite is intended to be used for the treatment of psoriasis and vitiligo. It is to be used on intact skin only. # Module Infrared 1550: The GME Flex.Sys System with Infrared 1550 module is indicated for use in dermatological procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures. It is also indicated for treatment of dyschromia and cutaneous lesions, such as, but not limited to lentigos (age spots), solar lentigos (sun spots), actinic keratosis, and melasma, and for treatment of periorbital wrinkles, acne scars and surgical scars. # G. Device Specifications and Comparison to Predicates [21 CFR 807.92(a)(6)] The FlexSys Platform is a multi-modality skin treatment device that can be equipped with up to six different modules. Thus, the predicate devices will vary from module to module. Three of these modules have already been approved, see K203054. Thus this comparison to predicates only deals with the remaining three modules, the Infrared 1550mm module and the two UVB 308nm modules. {5}------------------------------------------------ The predicate devices used to argue substantial equivalence are the GME ExSys 308 (K150752) and Clarteis Exciplex (K171702, K191086) for the UVB 308nm modules, and the Solta Fraxel DUAL (K130193) for the Infrared 1550nm module. The equivalence comparisons for the UVB 308 nm wavelengths use the predicates GME ExSys 308 and Clarteis Exciplex. The equivalence comparisons for the infrared 1550 nm laser wavelength use the predicate Solta Fraxel DUAL. | Characteristic | GME FlexSys
System
Module EPL 308
"FlexSys EPL 308" | GME FlexSys
System
Module EPL 308 lite
"FlexSys EPL 308 lite" | GME ExSys 308
"ExSys 308" | Clarteis
Exciplex308nm
"Exciplex" | |----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------| | Applicable 510(k)s | NA | NA | K150752 | K171702, K191086 | | Panel/ | General and Plastic
Surgery | General and Plastic
Surgery | General and Plastic
Surgery | General and Plastic
Surgery | | Product Code/ | FTC | FTC | FTC | FTC | | Regulation
Number | 21 CFR 878.4630 | 21 CFR 878.4630 | 21 CFR 878.4630 | 21 CFR 878.4630 | | Indications for Use
Statement | The GME FlexSys
System with module
EPL 308 is intended
to be used for the
treatment of
psoriasis and
vitiligo. It is to be
used on intact skin
only | The GME FlexSys
System with module
EPL 308 lite is
intended to be used
for the treatment of
psoriasis and
vitiligo. It is to be
used on intact skin
only | The GME ExSys
308 System is
intended to be used
for the treatment of
psoriasis and
vitiligo. It is to be
used on intact skin
only. | The Exciplex308nm
is intended to be
used for the
treatment of
psoriasis, vitiligo,
atopic dermatitis,
and leukoderma. | | Classification | Class II | Class II | Class II | Class II | | Common Name | Ultraviolet lamp for
dermatologic
disorders | Ultraviolet lamp for
dermatologic
disorders | Ultraviolet lamp for
dermatologic
disorders | Ultraviolet lamp for
dermatologic
disorders | | Mechanism of
Action | UVB light
penetrates the skin
and modulates the
immune system and
stimulates
melanocytes to
produce melanin | UVB light
penetrates the skin
and modulates the
immune system and
stimulates
melanocytes to
produce melanin | UVB light
penetrates the skin
and modulates the
immune system and
stimulates
melanocytes to
produce melanin | UVB light
penetrates the skin
and modulates the
immune system and
stimulates
melanocytes to
produce melanin | # 1. UVB modules # 2. Infrared 1550 module | Characteristic | GME FlexSys System | Solta Fraxel DUAL
1550/1927 Laser System | |----------------|----------------------------|---------------------------------------------| | - | Module Infrared 1550 | | | - | "FlexSys Infrared
1550" | "Fraxel" | {6}------------------------------------------------ | Applicable
510(k)s | NA | K130193 | |----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Panel/ | General and Plastic
Surgery | General and Plastic Surgery | | Product Code/ | GEX | GEX | | Regulation
Number | 21 CFR 878.4810 | 21 CFR 878.4810 | | Indications for
Use Statement | The GME FlexSys
System with Infrared
1550 module is indicated
for use in dermatological
procedures requiring the
coagulation of soft tissue,
as well as for skin
resurfacing procedures. It
is also indicated for
treatment of dyschromia
and cutaneous lesions,
such as, but not limited to
lentigos (age spots), solar
lentigos (sun spots),
actinic keratosis, and
melasma, and for
treatment of periorbital
wrinkles, acne scars and
surgical scars. | The Fraxel 1550 nm laser is
indicated for use in
dermatological procedures
requiring the coagulation of
soft tissue, as well as for skin
resurfacing procedures. It is
also indicated for treatment of
dyschromia and cutaneous
lesions, such as, but not
limited to lentigos (age spots),
solar lentigos (sun spots),
actinic keratosis, and
melasma, and for treatment of
periorbital wrinkles, acne
scars and surgical scars. | | Classification | Class II | Class II | | Common Name | Laser surgical instrument
for use in general and
plastic surgery and in
dermatology | Laser surgical instrument for
use in general and plastic
surgery and in dermatology | | Mechanism of
Action | Heats water in skin
through the absorption of
light. The heating
denatures the skin and
stimulates a healing
reaction by the skin. | Heats water in skin through
the absorption of light. The
heating denatures the skin and
stimulates a healing reaction
by the skin. | #### H. Performance Data [21 CFR 807.92(b)(2)] The Guidance Document, Laser Products – Conformance with IEC 60825-1 and IEC 60601-2-22 (Laser Notice 56) January 19, 2018 was used. Testing reports were submitted for the following standards: - IEC 60825-1 Edition 2.0 2007-03: Safety of Laser Products Part 1: Equipment -Classification, and Requirements - IEC 60601-2-22 Edition 3.1 2012-10: Medical Electrical Equipment Part 2-22: -Particular Requirements for Basic Safety and Essential Performance of Surgical, Cosmetic, Therapeutic and Diagnostic Laser Equipment - -IEC 60601-1:2005, AMD1:2012: Medical Electrical Equipment – Part 1: General Requirements for Basic Safety and Essential Performance {7}------------------------------------------------ - -IEC 60601-1-2:2014: Medical Equipment – Part 1-2: General Requirements for Basic Safety and Essential Performance – Collateral Standard: Electromagnetic Compatibility – Requirements and Tests - I. Conclusion [21 CFR 807.92(b)(3)] The GME FlexSys System is substantially equivalent to the predicate devices; in terms of technology, function and indications for use. There are no new questions of safety or efficacy raised by the introduction of the FlexSys System. --- **Source:** [https://fda-staging.innolitics.com/device/K221623](https://fda-staging.innolitics.com/device/K221623) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com